IASLC Resources for SBOC Annual Meeting

Celebrating the collaborative network between the IASLC and our Brazilian members.
SBOC 2023

The IASLC proudly celebrates our Association's rich and vibrant history, intertwined with our Brazillian members' invaluable contributions and dedicated participation. Over the years, our organization has cultivated deep-rooted connections with experts from Brazil, fostering a spirit of collaboration and cultural exchange. This engagement has played an integral role in shaping our collective journey, and we are excited to share the remarkable resources of this enduring partnership with you and explore the shared experiences and achievements that have defined our unique Association.

To view this page in Portuguese, scroll to the top of the page and select "Portuguese" as your preferred language translation. 

IASLC Membership is open to any

Patient/Survivors and Caregivers Icon
Patient/Survivor & Caregiver
Industry Members
Industry Member
Allied Health Professionals
Allied Health Professional
Others Interested in Thoracic Cancers.
Others Interested in Thoracic Cancers

Become an IASLC Member!

In recognition of the partnership SBOC has with the IASLC, we are excited to offer a special join rate during this meeting for a $75 1-Year Regular Membership or a $25 1-Year Allied Health Professional membership! Scan here to sign up to receive the discount code.
For first-time members only.

SBOC Interest Form

For questions regarding membership at the IASLC, please email membership@iaslc.org  

Engagement Opportunities With IASLC

Lung Cancer Considered Podcasts

LCC in Portuguese: Treating Lung Cancer in Brazil

This episode of Lung Cancer Considered is recorded entirely in Portuguese and focuses on lung cancer in Brazil.

LALCA 2023 Highlights

The Latin American Conference on Lung Cancer, held in Uruguay, wrapped up in late January of 2023. This episode provides a summary of key findings from the meeting.

Treating EGFR Mutant NSCLC in Brazil

This episode examines the treatment of EGFR-positive lung cancer in Brazil, from early-stage disease to metastatic lung cancer.


Through partnering with the IASLC Foundation, other foundations, nonprofits, corporations, and individual donors, the IASLC provides funding opportunities each year to facilitate research advances and save lives.

Upcoming IASLC Meetings

2024 Targeted Therapies of Lung Cancer Meeting

The IASLC Targeted Therapies of Lung Cancer Meeting is a dynamic meeting with a long tradition of summarizing data on relevant targets for new therapies and sharing data on...

2024 European Lung Cancer Congress

ELCC 2024 is taking place in Prague, Czech Republic, from 20-23 March 2024. ELCC 2024 is a collaborative effort of important multidisciplinary societies working together to advance...

2024 World Conference on Lung Cancer

Join us for the IASLC 2024 World Conference on Lung Cancer in San Diego, California from September 7-10, 2024. The WCLC has played an integral part in facilitating progress by...

2024 Asia Conference on Lung Cancer

The IASLC 2024 Asia Conference on Lung Cancer will take place October 17-19, 2024 in Hong Kong. ACLC will explore the latest developments in clinical & basic research, clinical...

IASLC Members receive discounted registration for our meetings. Complimentary registration is available for survivors, caregivers, and advocates. 

JTO Articles

Lung Cancer in Brazil

Lung cancer is one of the most common incident cancers and a leading cause of cancer mortality in Brazil. Here, we aim to describe some aspects related to its prevention, diagnosis...

EP08.02-30 Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120)

Lung cancer is the leading cause of cancer death worldwide. Durvalumab was the first immune checkpoint inhibitor to demonstrate overall survival(OS) and progression-free survival...

P2.28-01 Lung Cancer Mortality in Brazil: Temporal Trends, Regional Disparities and the Impact of the COVID-19 Pandemic

Lung cancer (LC) ranks as the fourth most common type of cancer in Brazil. It also leads in mortality. Despite improvements in access to innovative treatments, there are...

PP.27 Clinical Outcomes of Stage III Non-small Cell Lung Cancer Patients Treated With Radical Radiotherapy in a Institution in Brazil

Lung cancer is the leading cause of cancer death. Most cases are diagnosed at advanced stages. Stage III cancers are treated in a curative manner, despite the low success rate. Our...

PD.02.06 Intensified Chemo-Immuno-Radiotherapy With Durvalumab for Stage Iii NSCLCS: A Brazilian Single Arm Phase Ii Study - Pacific Brazil (LACOG 2218)

Standard treatment of unresectable stage III NSCLC consists of concurrent chemoradiotherapy, followed by immunotherapy for 12 months, based on the results of the PACIFIC trial. The...

Pre-Order Your Copy of The 50th Anniversary Book!

We are getting ready to celebrate IASLC's 50th anniversary in 2024! Don't miss out, pre-order your copy of the book today.